Wegovy Cost in Utah 2026: Cash Price, Insurance, Medicaid, and Compounded Semaglutide

What Is the Cash Price of Wegovy in Utah in 2026?

The Novo Nordisk wholesale acquisition cost (WAC) for Wegovy is $1,349 per month in 2026, and Utah retail pharmacies track that list price closely when no insurance applies. Patients paying cash at chains such as Smith's, CVS, or Harmons will typically see a price in the $1,300 to $1,349 range before any discount card is applied. That figure covers a four-pen carton of the prescribed maintenance dose (2.4 mg/0.75 mL auto-injector), used once weekly.

Why the Price Varies Slightly by Pharmacy

Pharmacy benefit managers negotiate different spread amounts. A GoodRx coupon or similar discount card at an in-network pharmacy can shave $30 to $80 off the sticker price, though that still leaves most patients paying well over $1,200 monthly. Mark-ups on the 0.25 mg, 0.5 mg, 1.0 mg, and 1.7 mg titration doses are proportionally lower, so early months of therapy cost less before reaching maintenance.

How the List Price Compares to Other GLP-1 Agents

Ozempic (semaglutide 1 mg, approved for type 2 diabetes) carries a similar WAC. Zepbound (tirzepatide 2.5 mg to 15 mg) lists at approximately $1,059 per month. Neither is automatically cheaper once insurance tiers and prior-authorization requirements are factored in. The FDA's label for Wegovy covers adults with a BMI ≥30 kg/m², or a BMI ≥27 kg/m² plus at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea, per the FDA prescribing information [1].

Does Utah Medicaid Cover Wegovy?

Utah Medicaid does not currently cover Wegovy (semaglutide 2.4 mg) for chronic weight management. The Utah Department of Health and Human Services follows a fee-for-service formulary that excludes anti-obesity medications as a drug class, in line with the federal Medicaid statute, which historically has not required coverage of weight-loss drugs. That means even clinically eligible patients on Medicaid face full out-of-pocket cost unless a separate program applies.

Federal Medicaid Context

Section 1927 of the Social Security Act historically categorized weight-loss drugs as an excluded class, giving states the authority to omit them without a waiver. A proposed federal rule in 2024 sought to extend GLP-1 anti-obesity coverage to Medicaid and Medicare Part D enrollees, but as of 2026 Utah has not adopted any state plan amendment to add Wegovy [2]. Patients enrolled in Utah's CHIP program face the same exclusion.

What Utah Medicaid Does Cover

If a Medicaid patient has type 2 diabetes and a prescriber orders semaglutide for glycemic control, the 1 mg or 2 mg Ozempic formulation may be covered under the diabetes drug benefit. That dose is lower than the 2.4 mg weight-management dose, so it should not be assumed equivalent. Patients should verify current formulary status directly with Utah Medicaid at 1-800-662-9651.

Which Private Insurance Plans Cover Wegovy in Utah?

Coverage among commercial plans in Utah is inconsistent. Employer-sponsored plans that include an anti-obesity medication (AOM) benefit, often called a "weight-management rider," may cover Wegovy after prior authorization. Plans that do not carry the rider exclude it entirely, regardless of clinical need.

Prior-Authorization Requirements

Most Utah commercial insurers that do cover Wegovy require all of the following before approving a claim: a qualifying BMI (typically ≥30, or ≥27 with a documented comorbidity), documentation of a prior structured weight-loss program lasting at least 90 days, and a prescriber attestation of medical necessity. The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists as preferred agents for patients with type 2 diabetes and obesity, which can support prior-auth letters [3].

Large Utah Employers and Self-Funded Plans

Self-funded employers under ERISA design their own formularies. Several large Utah employers (including some state government plans) explicitly excluded AOMs as of 2025. Utah's Public Employee Benefit and Insurance Program (PEHP) should be contacted directly for 2026 plan-year updates, as formulary changes are announced annually in October.

Checking Your Specific Plan

Call the member services number on your insurance card and ask: "Is semaglutide 2.4 mg (Wegovy, NDC 00169-4796-12) covered under my pharmacy benefit, and what are the prior-authorization criteria?" Getting the answer in writing speeds the appeals process if a claim is denied.

How the Novo Nordisk Savings Card Works in Utah

Novo Nordisk offers the Wegovy Savings Card through the NovoCare program. Eligible commercially insured patients can pay as little as $0 per month for up to 24 months, with a maximum savings of $1,800 per 28-day supply. Cash-paying patients receive a reduced benefit: typically a $500 per-fill reduction, which still leaves a significant balance given the $1,349 WAC.

Eligibility Rules That Utah Patients Often Miss

The savings card excludes patients whose primary insurance is a federal program, including Medicare, Medicaid, TRICARE, and VA benefits. A Utah patient on Medicaid who is also enrolled in a commercial plan through a spouse's employer could qualify, but must ensure their commercial plan is listed as primary. Income limits do not apply to the savings card itself, though they do apply to the NovoCare Patient Assistance Program (PAP), which provides Wegovy at no cost to uninsured patients below 400% of the federal poverty level.

Applying for the Savings Card

Enrollment is completed at the Novo Nordisk NovoCare website or at the pharmacy counter using a printed card. Pharmacists at major Utah chains are familiar with the process. The card is tied to a specific NDC, so ensure the prescription is written for Wegovy specifically, not a generic semaglutide.

Is Compounded Semaglutide 2.4 mg Legal in Utah?

Yes, with significant caveats. During an active FDA drug shortage, 503A compounding pharmacies (state-licensed pharmacies compounding for individual patients) may prepare copies of a shortage drug, including semaglutide. Wegovy was listed on the FDA drug shortage database from 2022 through much of 2024. The FDA removed semaglutide injection from the shortage list in 2024, which triggered a phaseout period for 503A compounding [4].

The 503A Phaseout Timeline and Utah Patients

After shortage removal, the FDA gave 503A pharmacies a wind-down period. Prescriptions initiated before the FDA's compliance deadline may still be dispensed legally, while new prescriptions from 503A pharmacies face greater regulatory scrutiny. Utah's 503B outsourcing facilities (which produce large-batch compounded drugs) were subject to a shorter compliance window. Patients currently receiving compounded semaglutide from a Utah 503A pharmacy should confirm their pharmacy's compliance status with the Utah Division of Occupational and Professional Licensing (DOPL).

Cost Comparison: Compounded vs. Brand

The table below shows a side-by-side cost framework for a Utah patient in 2026 across the most common access pathways. A HealthRX clinical pharmacist developed this framework based on current Utah pharmacy survey data.

| Access pathway | Monthly cost (Utah, 2026) | Insurance applies? | FDA-approved product? | |---|---|---|---| | Wegovy brand, cash pay | $1,349 | No | Yes | | Wegovy brand, savings card (commercially insured) | $0 to $25 | Yes | Yes | | Wegovy brand, savings card (uninsured) | ~$849 | No | Yes | | Compounded semaglutide 2.4 mg, 503A | ~$199 | No (typically) | No | | NovoCare PAP (income-eligible, uninsured) | $0 | No | Yes |

The $199 compounded price is meaningful. For a patient paying cash and ineligible for the savings card, compounded semaglutide may reduce annual spending by more than $13,800. The trade-off: compounded products are not FDA-approved for safety, efficacy, or sterility at the individual batch level, and potency variability has been documented [5].

What Utah Telehealth Platforms Are Prescribing

Telehealth is legal for Wegovy prescribing in Utah. Providers licensed in Utah may prescribe after a synchronous audio-visual consultation. Many Utah telehealth platforms default to prescribing compounded semaglutide through affiliated 503A pharmacies as the lower-cost option. Patients should ask specifically which product, and from which pharmacy, before initiating therapy.

Clinical Efficacy: What the Evidence Says

The price tag becomes more defensible once the clinical data are reviewed. STEP-1, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity (BMI ≥30) or overweight (BMI ≥27) plus at least one weight-related comorbidity. Participants received semaglutide 2.4 mg once weekly or placebo over 68 weeks. The semaglutide group lost a mean of 14.9% of body weight versus 2.4% in the placebo group (P<0.001) [6].

SELECT Trial: Cardiovascular Benefit

The SELECT trial (N=17,604), published in the New England Journal of Medicine in November 2023, showed that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% compared with placebo in adults with established cardiovascular disease and overweight or obesity but without diabetes [7]. The FDA subsequently approved a cardiovascular risk-reduction indication for Wegovy in March 2024, which has strengthened coverage arguments for commercially insured patients with existing heart disease.

Dosing Schedule That Affects Cost Over Time

Wegovy is initiated at 0.25 mg weekly for four weeks, then escalated through 0.5 mg, 1.0 mg, and 1.7 mg over 16 weeks before reaching the 2.4 mg maintenance dose. Each titration dose is dispensed as a separate carton with a lower WAC than the 2.4 mg strength, so the first four months of treatment carry a lower monthly cost. Patients who cannot tolerate 2.4 mg may maintain therapy at 1.7 mg per the FDA prescribing label [1].

Side-Effect Profile That May Affect Adherence and Cost

Nausea affects roughly 44% of Wegovy users in the first eight weeks, per STEP-1 data, and is the leading reason for dose delay or discontinuation [6]. Patients who discontinue early have paid titration-dose costs without reaching therapeutic benefit. Prescribers at Utah telehealth platforms and in-person clinics typically prescribe ondansetron 4 mg as needed for the first two months, adding a modest but manageable pharmacy cost.

How to Get the Lowest Wegovy Price in Utah: A Step-by-Step Approach

Step 1: Check Your Insurance Formulary First

Log in to your insurer's online formulary tool and search for "semaglutide 2.4 mg" or "Wegovy." Note the tier, copay, and prior-auth requirements. If it is covered, this path almost always produces the lowest net cost after the savings card layers on top.

Step 2: Apply for the Novo Nordisk Savings Card Immediately

Even before filling the first prescription, enroll at NovoCare. The card activates the same day and can be used at the pharmacy during pickup. Commercially insured Utah patients who qualify may pay $0 for up to 24 months.

Step 3: If Uninsured and Income-Eligible, Apply for the PAP

The NovoCare Patient Assistance Program provides free Wegovy to uninsured patients below 400% of the federal poverty level. At 2026 federal poverty levels, that is approximately $60,240 for an individual. The application requires a prescriber signature and income documentation and takes two to four weeks.

Step 4: Evaluate Compounded Semaglutide Only After Legal Verification

If brand Wegovy remains unaffordable, ask your prescriber specifically whether a Utah 503A pharmacy is currently permitted to compound semaglutide under federal compliance guidelines. Do not assume legality based on a telehealth platform's marketing. Request the pharmacy's DOPL license number and confirm compounding authorization.

Step 5: Revisit Coverage Annually

Utah employer plans update formularies every January 1. If your plan excluded Wegovy in 2025, the 2026 plan document may differ. The SELECT trial's cardiovascular indication has prompted some Utah self-funded employers to reconsider exclusions for high-risk employee populations.

Utah-Specific Prescribing Field

Utah has a growing concentration of obesity medicine specialists, particularly along the Wasatch Front. The Utah Medical Association does not maintain a specific AOM prescribing registry, but board-certified obesity medicine physicians (credentialed through the American Board of Obesity Medicine) practice at University of Utah Health, Intermountain Health, and multiple independent weight-management clinics in Salt Lake City, Provo, and St. George.

Telehealth Prescribing Rules in Utah

Utah follows Ryan Haight Act requirements for controlled substances, but semaglutide is not a controlled substance, so telehealth prescribing faces no DEA registration barrier beyond standard licensure. A prescriber must hold an active Utah license and conduct a compliant clinical evaluation. The FDA's guidance on GLP-1 prescribing via telehealth does not restrict the modality for non-controlled medications [8].

Getting a Prescription Without a Local Visit

Several Utah-licensed telehealth platforms offer asynchronous intake (questionnaire plus photo or lab upload) followed by a synchronous video call. A clinical evaluation for Wegovy typically requires: current weight and height (BMI calculation), a recent metabolic panel or willingness to obtain one, documentation of prior weight-loss attempts, and a medication and allergy history. Many Utah labs, including ARUP Laboratories (based in Salt Lake City), offer direct-pay metabolic panels under $60 that satisfy this requirement.

Monitoring Costs Beyond the Drug Itself

The full cost of Wegovy therapy includes more than the monthly prescription. Utah patients should budget for: a baseline hemoglobin A1c and lipid panel ($40 to $120 cash at ARUP or LabCorp Utah locations), quarterly check-ins with a prescriber ($0 to $200 depending on telehealth platform), and auto-injector supplies (needles are integrated into the Wegovy FlexTouch pen, so no separate needle purchase is needed). Patients who develop gallstones, a known adverse effect occurring in approximately 1.6% of STEP-1 participants at 68 weeks, may face additional diagnostic costs [6].

The Endocrine Society's 2023 Clinical Practice Guideline on Pharmacological Management of Obesity recommends monitoring weight, blood pressure, and heart rate at each clinical contact during GLP-1 therapy, and reassessing metabolic labs at 12 weeks [9]. Factoring those visits into the annual budget gives a realistic total-cost picture.